WO2016160968A1 - Compositions et procédés de traitement de la leucémie aiguë myéloïde - Google Patents

Compositions et procédés de traitement de la leucémie aiguë myéloïde Download PDF

Info

Publication number
WO2016160968A1
WO2016160968A1 PCT/US2016/024980 US2016024980W WO2016160968A1 WO 2016160968 A1 WO2016160968 A1 WO 2016160968A1 US 2016024980 W US2016024980 W US 2016024980W WO 2016160968 A1 WO2016160968 A1 WO 2016160968A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
aml
patients
population
Prior art date
Application number
PCT/US2016/024980
Other languages
English (en)
Inventor
David Avigan
Jacalyn ROSENBLATT
Donald Kufe
Original Assignee
Dana-Farber Cancer Institute, Inc.
Beth Israel Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/563,151 priority Critical patent/US20180078650A1/en
Application filed by Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center filed Critical Dana-Farber Cancer Institute, Inc.
Priority to CA2977753A priority patent/CA2977753A1/fr
Priority to EP16718545.3A priority patent/EP3277291A1/fr
Priority to AU2016243194A priority patent/AU2016243194A1/en
Publication of WO2016160968A1 publication Critical patent/WO2016160968A1/fr
Priority to HK18108369.6A priority patent/HK1248567A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des méthodes de traitement de la leucémie aiguë myéloïde.
PCT/US2016/024980 2015-03-30 2016-03-30 Compositions et procédés de traitement de la leucémie aiguë myéloïde WO2016160968A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/563,151 US20180078650A1 (en) 2015-03-30 2015-03-30 Compositions and methods of treating acute myeloid leukemia
CA2977753A CA2977753A1 (fr) 2015-03-30 2016-03-30 Compositions et procedes de traitement de la leucemie aigue myeloide
EP16718545.3A EP3277291A1 (fr) 2015-03-30 2016-03-30 Compositions et procédés de traitement de la leucémie aiguë myéloïde
AU2016243194A AU2016243194A1 (en) 2015-03-30 2016-03-30 Compositions and methods of treating acute myeloid leukemia
HK18108369.6A HK1248567A1 (zh) 2015-03-30 2018-06-28 治療急性髓性白血病的組合物和方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562140325P 2015-03-30 2015-03-30
US62/140,325 2015-03-30
US201562257943P 2015-11-20 2015-11-20
US62/257,943 2015-11-20

Publications (1)

Publication Number Publication Date
WO2016160968A1 true WO2016160968A1 (fr) 2016-10-06

Family

ID=55808849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/024980 WO2016160968A1 (fr) 2015-03-30 2016-03-30 Compositions et procédés de traitement de la leucémie aiguë myéloïde

Country Status (5)

Country Link
EP (1) EP3277291A1 (fr)
AU (1) AU2016243194A1 (fr)
CA (1) CA2977753A1 (fr)
HK (1) HK1248567A1 (fr)
WO (1) WO2016160968A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CN111088360A (zh) * 2020-01-17 2020-05-01 暨南大学 Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用
EP3568471A4 (fr) * 2017-01-11 2020-08-26 Dana-Farber Cancer Institute, Inc. Vaccins personnalisés

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000655A1 (fr) 1993-06-24 1995-01-05 Mc Master University Vecteurs a base d'adenovirus destines a la therapie genique
WO1995011984A2 (fr) 1993-10-25 1995-05-04 Canji, Inc. Vecteur recombinant d'adenovirus et procedes d'utilisation
WO1995027071A2 (fr) 1994-04-04 1995-10-12 Board Of Regents, The University Of Texas System Systeme supervecteur adenoviral
US6653848B2 (en) 2000-09-18 2003-11-25 Agilent Technologies, Inc. Method and apparatus for linear characterization of multi-terminal single-ended or balanced devices
WO2009062001A1 (fr) * 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation de l'immunité anticancéreuse à l'aide de fusions de cellules dendritiques/cellules tumorales et anti-cd3/cd28

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000655A1 (fr) 1993-06-24 1995-01-05 Mc Master University Vecteurs a base d'adenovirus destines a la therapie genique
WO1995011984A2 (fr) 1993-10-25 1995-05-04 Canji, Inc. Vecteur recombinant d'adenovirus et procedes d'utilisation
WO1995027071A2 (fr) 1994-04-04 1995-10-12 Board Of Regents, The University Of Texas System Systeme supervecteur adenoviral
US6653848B2 (en) 2000-09-18 2003-11-25 Agilent Technologies, Inc. Method and apparatus for linear characterization of multi-terminal single-ended or balanced devices
WO2009062001A1 (fr) * 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation de l'immunité anticancéreuse à l'aide de fusions de cellules dendritiques/cellules tumorales et anti-cd3/cd28

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
ALLAVENA ET AL., EUR. J. IMMUNOL., vol. 28, 1998, pages 359 - 69
ALLEN M. ET AL., HUMAN IMM., vol. 40, 1994, pages 25 - 32
ASAVAROENHCHAI ET AL., PROC NATL ACAD SCI USA, vol. 99, 2002, pages 931 - 36
ASHLEY ET AL., J EXP MED, vol. 186, 1997, pages 1177 - 82
ATHALIA R PYZER ET AL: "Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 10, no. 11, 2 November 2014 (2014-11-02), US, pages 3125 - 3131, XP055280023, ISSN: 2164-5515, DOI: 10.4161/21645515.2014.982993 *
AVIGAN, BLOOD REV., vol. 13, 1999, pages 51 - 64
BANCHEREAU ET AL., NATURE, vol. 392, 1998, pages 245 - 52
BENDER ET AL., J. IMMUN. METH., vol. 196, 1996, pages 121 - 135
DHODAPKAR ET AL., J EXP MED., vol. 193, 2001, pages 233 - 38
F. M. AUSUBEL ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1987
FREEMAN ET AL., SCIENCE, vol. 262, 1993, pages 909 - 911
FRESHNEY: "ANIMAL CELL CULTURE", 1987
FREUDENTHAL ET AL., PROC. NATL ACAD SCI USA, vol. 87, 1990, pages 7698
GABRILOVICH ET AL., BLOOD, vol. 92, 1998, pages 4150 - 66
GABRILOVICH ET AL., CLIN CANCER RES., vol. 3, 1997, pages 483 - 90
GABRILOVICH, NAT REV IMMUNOL, vol. 4, 2004, pages 941 - 52
HERMONAT; MUZYCZKA, PNAS USA, vol. 81, 1984, pages 6466 - 6470
HURLEY C.K. ET AL., TISSUE ANTIGENS, vol. 50, 1997, pages 401 - 415
INABA ET AL., J. EXP, MED, vol. 176, 1992, pages 1693 - 1702
INABA ET AL., J. EXP. MED, vol. 175, 1992, pages 1157
JACALYN ROSENBLATT: "Abstract 948:Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission", 53RD ASH ANNUAL MEETING AND EXPOSITION 2011, 13 December 2011 (2011-12-13), XP055280031, Retrieved from the Internet <URL:https://ash.confex.com/ash/2011/webprogram/Paper39193.html> [retrieved on 20160613] *
LEBKOWSKI ET AL., MOL CELL BIOL, vol. 8, 1988, pages 3988 - 3996
M. KLAMMER ET AL: "Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia", BRITISH JOURNAL OF HAEMATOLOGY, vol. 129, no. 3, 1 May 2005 (2005-05-01), GB, pages 340 - 349, XP055280081, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2005.05477.x *
MACPHERSON, B.D. HAMES AND G.R. TAYLOR: "METHODS IN ENZYMOLOGY", 1995, ACADEMIC PRESS, INC.
MARTIN: "REMINGTON'S PHARM. SCI, 15th ed.", 1975, MACK PUBL. CO.
NABAVI ET AL., NATURE, vol. 360, pages 266
RICHARD M STONE ET AL: "Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients | Blood Journal", BLOOD, 1 January 2013 (2013-01-01), XP055280387, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/122/21/3928> [retrieved on 20160614] *
ROMANI ET AL., J. EXP. MED., vol. 180, 1994, pages 83 - 93
ROMANI ET AL., J. IMMUN. METH, vol. 196, 1996, pages 137 - 151
ROMANI ET AL., J. INVEST. DERMATOL, vol. 93, 1989, pages 600
ROSENBLATT J ET AL: "Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION; 2012 BMT TANDEM MEETINGS, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US; SAN DIEGO, CA, USA, vol. 18, no. 2, Supplement, 1 February 2012 (2012-02-01), pages S289, XP028883150, ISSN: 1083-8791, [retrieved on 20120109], DOI: 10.1016/J.BBMT.2011.12.504 *
ROSENBLATT JACALYN ET AL: "Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION; 2014 BMT TANDEM MEETINGS, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US; GRAPEVINE, TX, USA, vol. 20, no. 2, Supplement, 1 February 2014 (2014-02-01), pages S50, XP028828270, ISSN: 1083-8791, [retrieved on 20140130], DOI: 10.1016/J.BBMT.2013.12.050 *
SALLUSTO ET AL., J. EXP. MED, vol. 179, 1994, pages 1109 - 1118
SAMBROOK; FRITSCH; MANIATIS: "MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed.", 1989
SANTAMARIA P. ET AL., HUMAN IMM., vol. 37, 1993, pages 39 - 50
SCHULER ET AL., J. EXP. MED, vol. 161, 1985, pages 526
STEINMAN ET AL., J. EXP. MED, vol. 149, 1979, pages 1
YOUNG ET AL., J. CLIN. INVEST, vol. 90, 1992, pages 229

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
EP3568471A4 (fr) * 2017-01-11 2020-08-26 Dana-Farber Cancer Institute, Inc. Vaccins personnalisés
CN111088360A (zh) * 2020-01-17 2020-05-01 暨南大学 Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用

Also Published As

Publication number Publication date
HK1248567A1 (zh) 2018-10-19
AU2016243194A1 (en) 2017-09-21
CA2977753A1 (fr) 2016-10-06
EP3277291A1 (fr) 2018-02-07

Similar Documents

Publication Publication Date Title
JP6230208B2 (ja) 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
CA2977836A1 (fr) Compositions et methodes de traitement du cancer
JP2011504101A5 (fr)
US11026921B2 (en) Compositions and methods of treating cancer
AU2016243192A1 (en) Compositions and methods of treating renal cell cancer
AU2016243626A1 (en) Compositions and methods of treating multiple myeloma
CA3012716A1 (fr) Fusions de vesicules extracellulaires et de cellules dendritiques et leurs methodes d&#39;utilisation
EP3277291A1 (fr) Compositions et procédés de traitement de la leucémie aiguë myéloïde
US20180078650A1 (en) Compositions and methods of treating acute myeloid leukemia
US20190269775A1 (en) Compositions and methods of treating cancer
CA3042945A1 (fr) Compositions et methodes de traitement du cancer
Theng The development and characterization of CD1a [superscript]+ dendritic cells from CD34 [superscript]+ progenitor cells isolated from human umbilical cord blood.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16718545

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2977753

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016243194

Country of ref document: AU

Date of ref document: 20160330

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2016718545

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15563151

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE